Development of a robust BH3 drug toolkit for precision medicine in hematologic malignancies

<b>Rationale:</b> In the era of precision medicine, there is a growing need for rapid reliable <i>ex vivo</i> functional assays capable of predicting treatment efficacy. One drug class that may particularly benefit from such assays is BH3 mimetics. These small molecules antagonize anti-apoptotic proteins such as BCL-2, MCL-1, or BCL-XL, on which cancer cells depend for their survival. A functional assay known as BH3 profiling was previously developed to measure those dependencies through the use of specific BH3-only peptides. A variation of this technique, dynamic BH3 profiling (DBP), allows for measuring changes in those dependencies, after <i>ex vivo</i> treatment with a drug of interest. Though well-validated to predict clinical response in hematologic malignancies, BH3 profiling technique requires the use of specialized BH3-only peptides and requires significant optimization to achieve reproducible results. <b>Methods:</b> We used a toolkit of BH3 mimetics drugs as probes instead of BH3-only peptides. This technique reduces the complexity and cost by using Annexin V/7AAD staining instead of cytochrome c release as a functional readout for apoptosis. We also used cell lines as internal controls for a representative response to BH3 mimetics that allow us to easily compare and stratify patients according to their profile. <b>Results:</b> We demonstrate that our new protocol enables apoptotic dependencies to be measured efficiently across different hematologic malignancies. In addition to a detailed description of the assay, we describe the results in several models including cell lines and primary tumor cells, both at baseline and dynamically after <i>ex vivo</i> drug treatments. We also compared BH3 toolkit baseline results on cell lines with those obtained using conventional BH3 profiling. <b>Conclusion:</b> Overall, our data validates this streamlined BH3 drug toolkit, allowing for a more extensive use of the BH3 profiling technique.

Authors

Institutions

Publication Details

Journal
Theranostics
Published
2025-04-21
DOI
https://doi.org/10.7150/thno.107852
Citations
1
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.94
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Development of a robust BH3 drug toolkit for precision medicine in hematologic malignancies

Jérôme Moreaux, Charles Herbaux, Sara Ovejero, Hugues de Boussac et al.
1 citations
Theranostics
Cancer Genomics and Diagnostics
0.94
article

Development of a robust BH3 drug toolkit for precision medicine in hematologic malignancies

Jérôme Moreaux, Charles Herbaux, Sara Ovejero, Hugues de Boussac, Caroline Molinaro, Valentin Jacquier, Ouissem Karmous Gadacha, Matthew Steven Davids, Alexandre Romero, Matthieu Abouladzé, Ludovic Gabellier, Ritu Somayaji
article en
1 citations

Abstract

<b>Rationale:</b> In the era of precision medicine, there is a growing need for rapid reliable <i>ex vivo</i> functional assays capable of predicting treatment efficacy. One drug class that may particularly benefit from such assays is BH3 mimetics. These small molecules antagonize anti-apoptotic proteins such as BCL-2, MCL-1, or BCL-XL, on which cancer cells depend for their survival. A functional assay known as BH3 profiling was previously developed to measure those dependencies through the use of specific BH3-only peptides. A variation of this technique, dynamic BH3 profiling (DBP), allows for measuring changes in those dependencies, after <i>ex vivo</i> treatment with a drug of interest. Though well-validated to predict clinical response in hematologic malignancies, BH3 profiling technique requires the use of specialized BH3-only peptides and requires significant optimization to achieve reproducible results. <b>Methods:</b> We used a toolkit of BH3 mimetics drugs as probes instead of BH3-only peptides. This technique reduces the complexity and cost by using Annexin V/7AAD staining instead of cytochrome c release as a functional readout for apoptosis. We also used cell lines as internal controls for a representative response to BH3 mimetics that allow us to easily compare and stratify patients according to their profile. <b>Results:</b> We demonstrate that our new protocol enables apoptotic dependencies to be measured efficiently across different hematologic malignancies. In addition to a detailed description of the assay, we describe the results in several models including cell lines and primary tumor cells, both at baseline and dynamically after <i>ex vivo</i> drug treatments. We also compared BH3 toolkit baseline results on cell lines with those obtained using conventional BH3 profiling. <b>Conclusion:</b> Overall, our data validates this streamlined BH3 drug toolkit, allowing for a more extensive use of the BH3 profiling technique.

TheranosticsVol. 15(12)
Centre National de la Recherche Scientifique (FR), Institut Universitaire de France (FR), Université de Montpellier (FR), Centre Hospitalier Universitaire de Montpellier (FR), Dana-Farber Cancer Institute (US), Institut de Génétique Humaine (FR)
Good health and well-being
Openalex Percentile: Top 26%
Cancer Genomics and Diagnostics
0.94
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.